The EDGE

Nicole Muller-Bérat Killmann 1932–2014 Leukemia pioneer

R P Gale and A Hochhaus

Leukemia 2014 28: 727-728; 10.1038/leu.2014.101

Editorial

Magnesium and lymphoma: opportunities in translation

S Van Laecke, E V Nagler and R Vanholder

Leukemia 2014 28: 729-731; 10.1038/leu.2013.327

Review

MicroRNA theragnostics for the clinical management of multiple myeloma OPEN

N Ahmad, S Haider, S Jagannathan, E Anaissie and J J Driscoll

Leukemia 2014 28: 732-738; advance online publication, September 12, 2013; 10.1038/leu.2013.262

Original Articles

MOLECULAR TARGETS FOR THERAPY

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential

L M Neri, A Cani, A M Martelli, C Simioni, C Junghanss, G Tabellini, F Ricci, P L Tazzari, P Pagliaro, J A McCubrey and S Capitani

Leukemia 2014 28: 739-748; advance online publication, July 29, 2013; 10.1038/leu.2013.226

ACUTE LEUKEMIAS

Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors

P V Sanchez, S T Glantz, S Scotland, M T Kasner and M Carroll

Leukemia 2014 28: 749-760; advance online publication, July 4, 2013; 10.1038/leu.2013.202

Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL

J A P Spijkers-Hagelstein, S S Pinhanços, P Schneider, R Pieters and R W Stam

Leukemia 2014 28: 761-769; advance online publication, August 20, 2013; 10.1038/leu.2013.245

CBFB–MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia OPEN

A Mandoli, A A Singh, P W T C Jansen, A T J Wierenga, H Riahi, G Franci, K Prange, S Saeed, E Vellenga, M Vermeulen, H G Stunnenberg and J H A Martens

Leukemia 2014 28: 770-778; advance online publication, September 4, 2013; 10.1038/leu.2013.257

Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT

A Ruggeri, G Sanz, H Bittencourt, J Sanz, A Rambaldi, F Volt, I Yakoub-Agha, J M Ribera, L Mannone, J Sierra, M Mohty, C Solano, S Nabhan, W Arcese, E Gluckman, M Labopin and V Rocha on behalf of Eurocord and Acute Leukemia Working Party of European Blood and Marrow Transplant Group

Leukemia 2014 28: 779-786; advance online publication, September 5, 2013; 10.1038/leu.2013.259

DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia

W S Stevenson, O G Best, A Przybylla, Q Chen, N Singh, M Koleth, S Pierce, T Kennedy, W Tong, S-Q Kuang and G Garcia-Manero

Leukemia 2014 28: 787-793; advance online publication, September 18, 2013; 10.1038/leu.2013.270

The role of different genetic subtypes of CEBPA mutated AML

A Fasan, C Haferlach, T Alpermann, S Jeromin, V Grossmann, C Eder, S Weissmann, F Dicker, A Kohlmann, S Schindela, W Kern, T Haferlach and S Schnittger

Leukemia 2014 28: 794-803; advance online publication, September 23, 2013; 10.1038/leu.2013.273

MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia

M Díaz-Beyá, S Brunet, J Nomdedéu, R Tejero, T Díaz, M Pratcorona, M Tormo, J M Ribera, L Escoda, R Duarte, D Gallardo, I Heras, M P Queipo de Llano, J Bargay, M Monzo, J Sierra, A Navarro and J Esteve on behalf of the Cooperative AML group CETLAM (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias)

Leukemia 2014 28: 804-812; advance online publication, September 27, 2013; 10.1038/leu.2013.281

STEM CELLS

The murine long-term multi-lineage renewal marrow stem cell is a cycling cell

L R Goldberg, M S Dooner, K W Johnson, E F Papa, M G Pereira, M Del Tatto, D M Adler, J M Aliotta and P J Quesenberry

Leukemia 2014 28: 813-822; advance online publication, August 30, 2013; 10.1038/leu.2013.252

CYTOGENETICS AND MOLECULAR GENETICS

Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm

J Menezes, F Acquadro, M Wiseman, G Gómez-López, R N Salgado, J G Talavera-Casañas, I Buño, J V Cervera, S Montes-Moreno, J M Hernández-Rivas, R Ayala, M J Calasanz, M J Larrayoz, L F Brichs, M Gonzalez-Vicent, D G Pisano, M A Piris, S Álvarez and J C Cigudosa

Leukemia 2014 28: 823-829; advance online publication, September 27, 2013; 10.1038/leu.2013.283

IMMUNOLOGY

In vitro generation of mature, naive antigen-specific CD8⁺ T cells with a single T-cell receptor by agonist selection

S Snauwaert, G Verstichel, S Bonte, G Goetgeluk, S Vanhee, Y Van Caeneghem, K De Mulder, C Heirman, H Stauss, M H M Heemskerk, T Taghon, G Leclercq, J Plum, A W Langerak, K Thielemans, T Kerre and B Vandekerckhove

Leukemia 2014 28: 830-841; advance online publication, October 4, 2013; 10.1038/leu.2013.285

GENOMICS, GENE THERAPY AND PROTEOMICS

Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation OPEN

E M Weissinger, J Metzger, C Dobbelstein, D Wolff, M Schleuning, Z Kuzmina, H Greinix, A M Dickinson, W Mullen, H Kreipe, I Hamwi, M Morgan, A Krons, I Tchebotarenko, D Ihlenburg-Schwarz, E Dammann, M Collin, S Ehrlich, H Diedrich, M Stadler, M Eder, E Holler, H Mischak, J Krauter and A Ganser

Leukemia 2014 28: 842-852; advance online publication, July 11, 2013; 10.1038/leu.2013.210

SENSITIVITY AND RESISTANCE TO THERAPY

SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis

J-V Malfuson, L Boutin, D Clay, C Thépenier, C Desterke, F Torossian, B Guerton, A Anginot, T de Revel, J-J Lataillade and M-C Le Bousse-Kerdilès

Leukemia 2014 28: 853-864; advance online publication, September 3, 2013; 10.1038/leu.2013.256

LYMPHOMA

Quantification of circulating Epstein–Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance

Y-L Kwong, A W K Pang, A Y H Leung, C-S Chim and E Tse

Leukemia 2014 28: 865-870; advance online publication, July 11, 2013; 10.1038/leu.2013.212

RelA and RelB cross-talk and function in Epstein–Barr virus transformed B cells

A Chanut, F Duguet, A Marfak, A David, B Petit, M Parrens, S Durand-Panteix, M Boulin-Deveza, N Gachard, I Youlyouz-Marfak, D Bordessoule, J Feuillard and N Faumont

Leukemia 2014 28: 871-879; advance online publication, September 23, 2013; 10.1038/leu.2013.274

MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma

Z-X Yan, L-L Wu, K Xue, Q-L Zhang, Y Guo, M Romero, C Leboeuf, A Janin, S-J Chen, L Wang and W-L Zhao

Leukemia 2014 28: 880-887; advance online publication, October 9, 2013; 10.1038/leu.2013.291

MYELOMA

Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia

X Papanikolaou, E R Rosenbaum, L N Tyler, J Sawyer, C J Heuck, B Barlogie and M Cottler-Fox

Leukemia 2014 28: 888-893; advance online publication, July 15, 2013; 10.1038/leu.2013.214

Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma

X Wang, Z Yan, M Fulciniti, Y Li, M Gkotzamanidou, S B Amin, P K Shah, Y Zhang, N C Munshi and C Li

Leukemia 2014 28: 894-903; advance online publication, August 8, 2013; 10.1038/leu.2013.233

Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies

M A Frassanito, L Rao, M Moschetta, R Ria, L Di Marzo, A De Luisi, V Racanelli, I Catacchio, S Berardi, A Basile, E Menu, S Ruggieri, B Nico, D Ribatti, R Fumarulo, F Dammacco, K Vanderkerken and A Vacca

Leukemia 2014 28: 904-916; advance online publication, September 2, 2013; 10.1038/leu.2013.254

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

J Chu, Y Deng, D M Benson, S He, T Hughes, J Zhang, Y Peng, H Mao, L Yi, K Ghoshal, X He, S M Devine, X Zhang, M A Caligiuri, C C Hofmeister and J Yu

Leukemia 2014 28: 917-927; advance online publication, September 26, 2013; 10.1038/leu.2013.279

VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT

E Terpos, D Christoulas, E Kastritis, M Roussou, M Migkou, E Eleutherakis-Papaiakovou, M Gavriatopoulou, M Gkotzamanidou, N Kanellias, E Manios, C Papadimitriou and M A Dimopoulos

Leukemia 2014 28: 928-934; advance online publication, September 18, 2013; 10.1038/leu.2013.267

Letters to the Editor

Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes

L Wang, S I Swierczek, J Drummond, K Hickman, SJ Kim, K Walker, H Doddapaneni, D M Muzny, R A Gibbs, D A Wheeler and J T Prchal

Leukemia 2014 28: 935-938; advance online publication, January 13, 2014; 10.1038/leu.2014.7

The relationship of JAK2^V617F and acquired UPD at chromosome 9p in polycythemia vera

L Wang, S I Swierczek, L Lanikova, S J Kim, K Hickman, K Walker, K Wang, J Drummond, H Doddapaneni, J G Reid, D M Muzny, R A Gibbs, D A Wheeler and J T Prchal

Leukemia 2014 28: 938-941; advance online publication, January 27, 2014; 10.1038/leu.2014.20

Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies

J A Ross, M Spadaro, D C Rosado, F Cavallo, R A Kirken and F Pericle

Leukemia 2014 28: 941-944; advance online publication, October 23, 2013; 10.1038/leu.2013.309

Whole-exome sequencing identifies a novel somatic mutation in MMP8 associated with a t(1;22)-acute megakaryoblastic leukemia

Y Kim, V P Schulz, N Satake, T A Gruber, A M Teixeira, S Halene, P G Gallagher and D S Krause

Leukemia 2014 28: 945-948; advance online publication, October 25, 2013; 10.1038/leu.2013.314

Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist

M Zhang, Z Luo, H Liu, C M Croce, T R Burke, Jr and D P Bottaro

Leukemia 2014 28: 948-951; advance online publication, October 31, 2013; 10.1038/leu.2013.323

Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma OPEN

R Silbermann, M Bolzoni, P Storti, D Guasco, S Bonomini, D Zhou, J Wu, J L Anderson, J J Windle, F Aversa, G David Roodman and N Giuliani

Leukemia 2014 28: 951-954; advance online publication, December 26, 2013; 10.1038/leu.2013.385

Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade OPEN

E M Grössinger, L Weiss, S Zierler, S Rebhandl, P W Krenn, E Hinterseer, J Schmölzer, D Asslaber, S Hainzl, D Neureiter, A Egle, J Piñón-Hofbauer, T N Hartmann, R Greil and H H Kerschbaum

Leukemia 2014 28: 954-958; advance online publication, January 20, 2014; 10.1038/leu.2014.37

Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy

C D DiNardo, N Daver, N Jain, N Pemmaraju, C Bueso-Ramos, C C Yin, S Pierce, E Jabbour, J E Cortes, H M Kantarjian, G Garcia-Manero and S Verstovsek

Leukemia 2014 28: 958-961; advance online publication, January 10, 2014; 10.1038/leu.2014.8

Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein

S Shukla, E E Chufan, S Singh, A P Skoumbourdis, K Kapoor, M B Boxer, D Y Duveau, C J Thomas, T T Talele and S V Ambudkar

Leukemia 2014 28: 961-964; advance online publication, January 14, 2014; 10.1038/leu.2014.21

Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children’s Oncology Group Study AALL0031

K R Schultz, M Devidas, W P Bowman, A Aledo, W B Slayton, H Sather, H W Zheng, S M Davies, P S Gaynon, M Trigg, R Rutledge, D Jorstad, A J Carroll, N Heerema, N Winick, M J Borowitz, S P Hunger, W L Carroll and B Camitta The Children’s Oncology Group

Leukemia 2014 28: 964-967; advance online publication, January 17, 2014; 10.1038/leu.2014.29

Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients OPEN

G Visani, F Ferrara, F Di Raimondo, F Loscocco, G Sparaventi, S Paolini, F Fuligni, A Gazzola, M Rossi, M A Laginestra, M R Caraci, C Riccardi, M Rocchi, A Visani, S A Pileri, P P Piccaluga and A Isidori

Leukemia 2014 28: 967-970; advance online publication, January 20, 2014; 10.1038/leu.2014.31

MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease

L Kordelas, V Rebmann, A-K Ludwig, S Radtke, J Ruesing, T R Doeppner, M Epple, P A Horn, D W Beelen and B Giebel

Leukemia 2014 28: 970-973; 10.1038/leu.2014.41

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience

P Jain, H Kantarjian, F Ravandi, D Thomas, S O'Brien, T Kadia, J Burger, G Borthakur, N Daver, E Jabbour, M Konopleva, J Cortes, N Pemmaraju, M A Kelly, M Cardenas-Turanzas, R Garris and S Faderl

Leukemia 2014 28: 973-975; advance online publication, October 25, 2013; 10.1038/leu.2013.312

Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib

K Mayer, G H Gielen, W Willinek, M C Müller and D Wolf

Leukemia 2014 28: 976-977; advance online publication, October 30, 2013; 10.1038/leu.2013.320

RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib

H Lilljebjörn, H Ågerstam, C Orsmark-Pietras, M Rissler, H Ehrencrona, L Nilsson, J Richter and T Fioretos

Leukemia 2014 28: 977-979; advance online publication, November 4, 2013; 10.1038/leu.2013.324

Corrigenda

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

C Visco, Y Li, Z Y Xu-Monette, R N Miranda, T M Green, Y Li, A Tzankov, W Wen, W-m Liu, B S Kahl, E S G d'Amore, S Montes-Moreno, K Dybkær, A Chiu, W Tam, A Orazi, Y Zu, G Bhagat, J N Winter, H-Y Wang, S O'Neill, C H Dunphy, E D Hsi, X F Zhao, R S Go, W W L Choi, F Zhou, M Czader, J Tong, X Zhao, J H van Krieken, Q Huang, W Ai, J Etzell, M Ponzoni, A J M Ferreri, M A Piris, M B Møller, C E Bueso-Ramos, L J Medeiros, L Wu and K H Young

Leukemia 2014 28: 980; 10.1038/leu.2014.24

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

R A Kyle and S V Rajkumar

Leukemia 2014 28: 980; 10.1038/leu.2014.11